Navigation Links
Rhythm's RM-131 Restores GI Function as a Potent Ghrelin Prokinetic
Date:5/9/2011

BOSTON, May 9, 2011 /PRNewswire/ -- Rhythm announced today results demonstrating that RM-131, the company's novel ghrelin agonist, was highly effective in restoring normal gastric function in animal models of delayed gastric emptying owing to a direct prokinetic effect. The results were the subject of an oral presentation by Lee M. Kaplan, MD, PhD (Massachusetts General Hospital, Harvard Medical School) titled "RM-131: A Potent Gastroprokinetic Agent" at the Digestive Disease Week 2011 conference in Chicago on Saturday, May 7, 2011.

"This study suggests RM-131's significant inherent potential for the treatment of common GI functional disorders such as diabetic gastroparesis," said Elizabeth Stoner, MD, Chief Development Officer of Rhythm. "Diabetic patients with gastroparesis experience high rates of hospitalization due to vomiting and nausea, and their ability to maintain glucose is significantly challenged by their inability to eat normally. We are developing RM-131 to improve outcomes for these types of GI disorders."

In this in vivo study, RM-131 fully restored gastric emptying in a progressive, dose-dependent manner and demonstrated 100 times greater potency compared with natural human ghrelin. In addition, RM-131 was shown to be more effective in restoring GI function compared with GHSR agonists such as ipamorelin. The study was performed by scientists at Ipsen who discovered RM-131.

"The results from this head-to-head testing are compelling and demonstrate RM-131's potential to restore impaired GI function," said Bart Henderson, President of Rhythm. "The diabetes epidemic is driving a significant increase in patients with gastroparesis, but patients today have very limited treatment options. RM-131 is now in Phase 1 human clinical trials to assess its potential for treating gastroparesis and other important functional GI disorders."

About Gastroparesis

Gastroparesis affects up to 30% of the 24 million diabetics in the U.S. and causes chronic nausea, vomiting, malnutrition, and a high rate of hospitalization. The U.S. economic cost of gastroparesis is estimated to total $3.5 billion, and annual hospitalization costs for diabetic gastroparesis exceed $200 million.

About RM-131

RM-131 is a small-peptide analog of ghrelin, a hormone produced in the stomach that stimulates gastrointestinal activity, mitigates proinflammatory cytokine production, and is the only hormone known to stimulate appetite. Derived from the natural ghrelin sequence, RM-131 has been optimized to stimulate gastrointestinal motility and anti-inflammatory activity, with enhanced stability and pharmacokinetics.

About Rhythm (www.rhythmtx.com)

Rhythm is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm investors include MPM Capital, New Enterprise Associates, and Third Rock Ventures. The company is based in Boston, Massachusetts.

Contact:
Bart Henderson
President
(617) 425-9219
bhenderson@rhythmtx.com


'/>"/>
SOURCE Rhythm
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. U.S. Hospital Sales Opportunities Maximized Through Functional Optimization
2. Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis
3. Premier Research Achieves Double-Digit Growth in Functional Sourcing for the Third Straight Year
4. RVX-208 Data Demonstrates Increase in Functional HDL Particles
5. CorMatrix Announces Pre-Clinical Data Suggesting Next Generation ECM Technology(TM) Can Improve Cardiac Function
6. Kidneys for Transplant Function Earlier and Last Longer When Preserved in a Machine Compared to the Traditional Box of Ice
7. Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling
8. NeuroFocus Names John Polich, World-Renowned Scientist in Brain Function and Cognition, to Head Global NeuroLab Operations
9. GeneCopoeia Introduces Genome-Wide MicroRNA (miRNA) Functional Analysis Tools
10. Kibow Biotech Strongly Supports World Kidney Day for Maintenance of Healthy Kidney Function
11. Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 system ... experiments and avoiding the use of exogenous expression plasmids. The simplicity of programming ... systematic gain-of-function studies. , This complement to loss-of-function studies, such as with ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... (ADC) therapeutics, today confirmed licensing rights that give it exclusive global access ... developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, an ...
(Date:10/10/2017)... CALIFORNIA (PRWEB) , ... October 10, 2017 , ... ... technological innovation and business process optimization firm for the life sciences and healthcare ... BoxWorks conference in San Francisco. , The presentation, “Automating GxP Validation for ...
Breaking Biology Technology:
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
(Date:3/30/2017)... 2017  On April 6-7, 2017, Sequencing.com will host ... hackathon at Microsoft,s headquarters in Redmond, ... on developing health and wellness apps that provide a ... Genome is the first hackathon for personal genomics ... companies in the genomics, tech and health industries are ...
(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
Breaking Biology News(10 mins):